-
1.发明申请公开(公告)号：US20180064786A1
公开(公告)日：2018-03-08
申请号：US15812342
申请日：2017-11-14
申请人： YALE UNIVERSITY
IPC分类号： A61K38/17 , A61K48/00 , C12N15/52 , C12N15/62 , C12N15/85 , C12N9/96 , C07K7/06 , A61K38/04 , C12Q1/68
CPC分类号： A61K38/1741 , A01K67/0271 , A01K2207/15 , A01K2207/20 , A01K2227/105 , A01K2267/0387 , A61K38/02 , A61K38/04 , A61K38/46 , A61K38/465 , A61K48/0058 , A61P9/10 , A61P13/12 , C07K7/06 , C07K14/745 , C07K2319/01 , C07K2319/30 , C07K2319/31 , C07K2319/33 , C07K2319/70 , C12N9/96 , C12N15/52 , C12N15/625 , C12N15/85 , C12N2840/007 , C12Q1/6883 , C12Y301/04001 , C12Y306/01009 , H05K999/99
摘要： The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
-
公开(公告)号：US12128087B2
公开(公告)日：2024-10-29
申请号：US17369830
申请日：2021-07-07
申请人： YALE UNIVERSITY
IPC分类号： A61K38/17 , A01K67/0271 , A61K38/02 , A61K38/04 , A61K38/46 , A61K48/00 , A61P9/10 , A61P13/12 , C07K7/06 , C07K14/745 , C12N9/96 , C12N15/52 , C12N15/62 , C12N15/85 , C12Q1/6883
CPC分类号： A61K38/1741 , A01K67/0271 , A61K38/02 , A61K38/04 , A61K38/46 , A61K38/465 , A61K48/0058 , A61P9/10 , A61P13/12 , C07K7/06 , C07K14/745 , C12N9/96 , C12N15/52 , C12N15/625 , C12N15/85 , C12Q1/6883 , C12Y301/04001 , C12Y306/01009 , A01K2207/15 , A01K2207/20 , A01K2227/105 , A01K2267/0387 , C07K2319/01 , C07K2319/30 , C07K2319/31 , C07K2319/33 , C07K2319/70 , C12N2840/007
摘要： The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
-
公开(公告)号：US20180318401A1
公开(公告)日：2018-11-08
申请号：US16033948
申请日：2018-07-12
申请人： YALE UNIVERSITY
CPC分类号： A61K38/465 , A61K38/46 , C07K2319/30 , C12N9/14 , C12N9/16 , C12Y301/04001 , C12Y306/01009
摘要： The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.
-
公开(公告)号：US09867870B2
公开(公告)日：2018-01-16
申请号：US15480986
申请日：2017-04-06
申请人： YALE UNIVERSITY
CPC分类号： A61K38/46 , A61K45/06 , C12N9/14 , C12N9/16 , C12N9/22 , C12Q1/44 , C12Y301/04001 , C12Y306/01009 , C12Y306/01029 , G01N33/5023 , G01N2333/916 , A61K2300/00
摘要： The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.
-
5.发明申请公开(公告)号：US20170340713A1
公开(公告)日：2017-11-30
申请号：US15672791
申请日：2017-08-09
申请人： YALE UNIVERSITY
IPC分类号： A61K38/46
CPC分类号： A61K38/1741 , A01K67/0271 , A01K2207/15 , A01K2207/20 , A01K2227/105 , A01K2267/0387 , A61K38/02 , A61K38/04 , A61K38/46 , A61K38/465 , A61K48/0058 , C07K7/06 , C07K14/745 , C07K2319/01 , C07K2319/30 , C07K2319/31 , C07K2319/33 , C07K2319/70 , C12N9/96 , C12N15/52 , C12N15/625 , C12N15/85 , C12N2840/007 , C12Q1/6883 , C12Y301/04001 , C12Y306/01009 , H05K999/99
摘要： The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
-
公开(公告)号：US20230372455A1
公开(公告)日：2023-11-23
申请号：US18058715
申请日：2022-11-23
发明人： David Thompson , Frank Rutsch , Yvonne Nitschke
CPC分类号： A61K38/46 , A61P9/10 , A61K38/38 , C12Y306/01009 , A61L31/08 , A61L31/16 , C07K2319/30 , A61L2300/416 , A61L2300/254 , A61L2300/252
摘要： The present disclosure provides compositions and methods for treating Peripheral Artery Diseases in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).
-
公开(公告)号：USRE49529E1
公开(公告)日：2023-05-16
申请号：US17111156
申请日：2020-12-03
申请人： Inozyme Pharma, Inc.
发明人： Anthony Quinn , Nelson Hsia , Tayeba Khan , Kim Lynette Askew , Gregory Grabowski , Zhiliang Cheng , W. Charles O'Neill
CPC分类号： A61K38/46 , A61P3/00 , A61P9/00 , A61P13/12 , C12N9/16 , C12Y301/04001 , C12Y306/01009 , C07K2319/30
摘要： The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
-
公开(公告)号：US20180318400A1
公开(公告)日：2018-11-08
申请号：US15536880
申请日：2015-12-18
发明人： Anthony Quinn , Nelson Hsia , Tayeba Khan , Kim Lynette Askew , Gregory Grabowski , Zhiliang Cheng , W.Charles O'Neill
CPC分类号： A61K38/46 , A61P3/00 , A61P9/00 , A61P13/12 , C07K2319/30 , C12N9/16 , C12Y301/04001 , C12Y306/01009
摘要： The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
-
公开(公告)号：US09913881B2
公开(公告)日：2018-03-13
申请号：US15466401
申请日：2017-03-22
申请人： YALE UNIVERSITY
CPC分类号： A61K38/465 , A61K38/46 , C07K2319/30 , C12N9/14 , C12N9/16 , C12Y301/04001 , C12Y306/01009
摘要： The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.
-
公开(公告)号：US20240148907A1
公开(公告)日：2024-05-09
申请号：US18297228
申请日：2023-04-07
发明人： Steven Jungles , Demetrios Braddock
CPC分类号： A61K48/0058 , A61P19/08 , C12N9/14 , C12N9/16 , C12N15/86 , C12Y301/04001 , C12Y306/01009 , C07K2319/30 , C12N2750/14143 , C12N2750/14171 , C12N2830/008
摘要： The present disclosure provides, among other things, vectors for expression of ENPP1 or ENPP3 in vivo and methods for the treatment of diseases of calcification and ossification in a subject.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.021 秒)
